EGFR positive

Utidelone plus capecitabine has brought therapeutic and survival benefits in the second-line treatment of patients with advanced breast cancer (ABC). Utidelone demonstrates favorable efficacy and safety in patients with refractory ABC, particularly in HR+/HER2- patients. The combination of utidelone with anti-angiogenic therapy shows promising intracranial anti-tumor activity and is expected to be a preferred option for ABC in subsequent lines of treatment.

SPDEF is specifically downregulated in TNBC, and its high expression is associated with earlier tumor stage and favorable clinical outcomes. SPDEF suppresses TNBC cell proliferation, migration, and invasion while promoting apoptosis through modulation of apoptosis-related protein expression, highlighting its potential as a prognostic biomarker and therapeutic target for TNBC.

This report of a patient with the rare p.(Cys797Ala) EGFR acquired mutation highlights the role of molecular modelling and IHC for phosphorylated proteins as tools to functionally characterize variants of unknown significance and help clinical decisions.

Baseline 18 F-FDG PET/CT may provide prognostic insights in HR+/HER2- metastatic breast cancer. High MTV and TLG are associated with poorer OS in univariate analyses but not in multivariable analyses. ECOG score > 0 and age ≥ 60 years are independent predictors of PFS.

Transcriptomic analysis in 19 patients indicates that high MuS is associated with immune activation and enrichment of cell-cycle and purine-metabolism pathways. The Mu-model provides non-invasive DFS prediction and recurrence risk stratification, while preliminarily exploring its potential to identify patients who may derive differential benefits from adjuvant therapy.

Even within T1 breast cancer, extensive nodal involvement (N2-3) defines a distinct subgroup with more aggressive tumor biology and significantly poorer survival, independent of other clinicopathological factors. This underscores the critical need for comprehensive nodal staging and potentially more intensive treatment strategies for T1N2-3 patients.

After propensity score matching (n=412), these differences persisted for treatment duration (12.9 vs. 6.8 months), CNS-rPFS (24.9 vs. 14.5 months), and OS (25.6 vs. 14.6 months), all P<0.001. In real-world practice, osimertinib is associated with longer first-line treatment duration, improved CNS control, and longer survival compared with gefitinib among EGFR-positive mNSCLC patients with brain metastases.

In summary, Arc exhibits potent anticancer activity against distinct breast cancer subtypes through multi-targeting mechanisms. Given the heterogeneity of breast cancer, Arc appears to be a promising candidate for further preclinical investigation.

The apparent survival disadvantage of ILC is largely explained by clinicopathologic features, with no independent association with OS. However, ILC demonstrates a time-dependent survival pattern, with lower early but higher late mortality, and worse outcomes in patients with extensive nodal involvement.

However, this evidence faces significant challenges, including methodological shortcomings and a high risk of bias and low GRADE level, which preclude its readiness for clinical translation. Future studies should standardize the methodological workflows in radiomics, conduct multicenter research, and thoroughly evaluate and discuss the validity of external validation.

Enrolled patients received 5 cycles of anlotinib (12 mg qd, d1‒14; q3w) plus 6 cycles of nab-paclitaxel (200 mg/m2, q3w), pirarubicin (50 mg/m2, q3w), and cyclophosphamide (500 mg/m2, q3w). Supporting evidence from an exploratory inverse probability of treatment weighting (IPTW) analysis using a real-world cohort receiving chemotherapy alone indicated a potential benefit of the combination over chemotherapy alone. In conclusion, neoadjuvant anlotinib plus chemotherapy demonstrates promising efficacy and manageable safety in HR+/HER2- breast cancer with a high Ki-67 index.

Among the 13,061 patients with pT1abN0M0 breast cancer, comprising 10,819 hormone receptor &lsqb;HR]-positive/HER2-negative, 1479 HER2-positive and 763 HR-negative/HER2-negative individuals, 92.4% of HR-positive/HER2-negative patients received endocrine therapy, 46.9% of HER2-positive patients received chemotherapy and/or anti-HER2 therapy, and 31.2% of HR-negative/HER2-negative patients received chemotherapy. This annual report provides a nationwide overview of contemporary systemic therapy patterns in small breast cancer and highlights size‑dependent and subtype‑specific use of systemic therapy in Japan, reflecting a risk‑adapted treatment strategy.